Nano Holdings, Inc. (4571) Stock Price

NANO MRNA's primary business is providing RNA drug development candidates to pharmaceutical companies to contribute to global health. The company has previously focused on developing innovative pharmaceuticals, particularly anticancer drugs, using micellar nanoparticle technology. However, in January 2023, it shifted its business model to specialize in nucleic acid drugs, including mRNA.

NANO MRNA pursues drug discovery and intellectual property acquisition in RNA therapeutics, adopting a model where it licenses out candidates to pharmaceutical companies upon entering late-stage clinical development. Leveraging its experience as a pioneer in mRNA drug research and development among domestic companies, it advances multiple pipelines in parallel.

The company's development programs focus on nucleic acid drugs: siRNA, antisense oligonucleotides (ASO), and mRNA. It primarily conducts mRNA drug discovery and is advancing regenerative medicine development for osteoarthritis of the knee. Going forward, it will pursue collaborative research with pharmaceutical companies and academia to expand its pipeline.

NANO MRNA operates an RNA drug discovery business that conducts non-clinical and early-stage clinical trials, then out-licenses the resulting development candidates to pharmaceutical companies. It leverages proprietary polymer drug delivery system (DDS) technology and lipid nanoparticles (LNP) to create high-quality assets.

The company's revenue model involves creating intellectual property through collaborative research with academia and companies pursuing RNA drug discovery, then out-licensing pharmaceutical candidates that have completed non-clinical or early-stage clinical trials to pharmaceutical companies. It receives milestone payments upon asset out-licensing and royalties upon successful development.

NANO MRNA's pipeline includes TUG1 ASO, RUNX1 mRNA, ophthalmology programs, immune tolerance vaccines, and PRDM14 siRNA. These projects are advanced through collaborative development with research institutions and companies both domestically and internationally.

NANO mRNA's primary business is providing RNA therapeutic development candidates to pharmaceutical companies to contribute to global health. The company specializes in nucleic acid therapeutics and leverages collaborations with other companies to advance efficient development.

NANO mRNA adopts a model in which it conducts drug discovery and intellectual property acquisition for RNA therapeutics, then licenses out candidates to pharmaceutical companies upon entering late-stage clinical development. This approach enables the company to advance multiple pipelines in parallel while aiming to become a global leader.

NANO mRNA operates an RNA drug discovery business that conducts preclinical and early-stage clinical trials, then out-licenses the resulting development candidates to pharmaceutical companies. The company creates high-quality assets by leveraging its proprietary polymer drug delivery system (DDS) technology and lipid nanoparticles (LNP).

The company's revenue model involves creating intellectual property through collaborative research with academia and companies pursuing RNA drug discovery, then out-licensing pharmaceutical candidates that have completed preclinical or early-stage clinical trials to pharmaceutical companies. NANO mRNA receives milestone payments upon asset out-licensing and royalties upon successful development.

NANO mRNA's growth strategy includes accelerating clinical trials, exploring mRNA seeds, and reviewing DDS technology. Through these initiatives, the company aims to establish proof-of-concept early and expand new projects to achieve sustained growth.